Can a cancer drug ease long COVID? new trial tests LAU-7b

NCT ID NCT05999435

Completed Symptom relief Sponsor: Laurent Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral drug called LAU-7b (fenretinide) in 272 adults with moderate to severe Long COVID symptoms lasting at least 12 weeks. Participants took the drug or a placebo in cycles of 14 days on, 14 days off, for 12 weeks. The main goal was to see if LAU-7b improves physical health and daily function compared to placebo. Results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LAU-7b (fenretinide)
What this could lead to: If it works, this could point toward a treatment that reduces physical symptoms and improves quality of life for people with Long COVID.
What could go wrong: This is a completed early-phase trial with modest size (272 people). Results are not yet published, so it's unclear if LAU-7b is better than placebo. Long COVID is complex and may not respond to a single drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID

Contacts and locations

Locations

CIUSS du Saguenay-Lac-St-Jean - Hôpital Chicoutimi

Chicoutimi, Quebec, G7H 5H6, Canada
Centre Hospitalier de l'Université de Sherbrooke

Sherbrooke, Quebec, J1H 5N4, Canada
Diex Recherche Québec Inc.

Québec, Quebec, G1V 4T3, Canada
Institut de Recherches Cliniques de Montréal

Montreal, Quebec, H2W 1R7, Canada
Montreal General Hospital

Montreal, Quebec, H3G 1A4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.